Judy Hejingdao Wu
Chief Operating Officer chez ASCLETIS PHARMA INC.
Fortune : 14 M $ au 30/04/2024
Profil
Judy Hejingdao Wu is currently working as a Director at Ascletis Biopharmaceutical (Hangzhou) Co. Ltd., as a Senior VP-Operations & Executive Director at Ascletis Pharma, Inc., as a Director & Vice President at Ascletis BioScience Co., Ltd., and as a Manager at Gannex LLC.
Previously, she worked as a Vice President at Ascletis Pharmaceuticals Co., Ltd.
Ms. Wu completed her undergraduate degree from Zhejiang University in 1996.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASCLETIS PHARMA, INC.
8,18% | 05/03/2024 | 82 827 414 ( 8,18% ) | 14 M $ | 30/04/2024 |
Postes actifs de Judy Hejingdao Wu
| Sociétés | Poste | Début |
|---|---|---|
| ASCLETIS PHARMA INC. | Chief Operating Officer | - |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Director/Board Member | - |
| Ascletis BioScience Co., Ltd. | Director/Board Member | 01/01/2014 |
| Gannex LLC | Corporate Officer/Principal | 01/01/2021 |
Anciens postes connus de Judy Hejingdao Wu
| Sociétés | Poste | Fin |
|---|---|---|
| Ascletis Pharmaceuticals Co., Ltd. | Corporate Officer/Principal | 01/12/2021 |
Formation de Judy Hejingdao Wu
| Zhejiang University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASCLETIS PHARMA INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
| Ascletis BioScience Co., Ltd. | |
| Gannex LLC | |
| Ascletis Pharmaceuticals Co., Ltd. |
